Stay updated on Nivolumab and Cyclophosphamide for R/R AML Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page.

Latest updates to the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page
- Check7 days agoChange DetectedRevision: v3.4.2 was added and Revision: v3.4.1 was removed in the page metadata. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check15 days agoChange DetectedRevision: v3.4.1 was added. The notices about government funding lapse and the previous Revision: v3.4.0 were removed.SummaryDifference0.4%

- Check22 days agoNo Change Detected
- Check30 days agoChange DetectedThe page now shows a glossary and adds QC-related metadata labels ('Last Update Submitted that Met QC Criteria') along with a revision note ('Revision: v3.4.0'), while older QC label, no-FEAR Act data note, and the prior revision label ('v3.3.4') were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check37 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check65 days agoChange DetectedAdded a Locations section listing Minnesota as the study site, and removed the Minnesota Locations entry and the HHS Vulnerability Disclosure link. The page revision was updated to v3.3.3.SummaryDifference0.2%

- Check86 days agoChange DetectedFooter revision indicator updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nivolumab and Cyclophosphamide for R/R AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page.